We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Rethinking AMD Policies After OIG Audit Notes Economics of Off-Label Avastin
CMS Rethinking AMD Policies After OIG Audit Notes Economics of Off-Label Avastin
September 7, 2011
Medicare Part B and patients could save millions of dollars each year if Avastin is used instead of Lucentis to treat wet age-related macular degeneration (AMD), and the Centers for Medicare and Medicaid Service (CMS) should consider that finding when making coverage and reimbursement decisions, an Office of Inspector General (OIG) audit concludes.